Dr. Castro and Dr. Rizzo discuss the evolving world of monoclonal antibodies for the treatment of severe asthma. Plus, the ALA team discusses September's annual Asthma Peak Week, and what it means for reopening schools.

See and read more Lungcast recaps and additional interviews at HCPLive.com/sap-partner/american-lung-association.

Listen to Dr. Rizzo's interview with Dr. Anne Dixon on the 2020 asthma management guidelines here.

Visit Lung.org for more resources and expert insights into respiratory disease management.

Episode highlights



0:15 Back to school with Asthma Peak Week

9:48 Biologics: the emerging severe asthma treatment field

11:34 Defining type 2 inflammation and severe asthma

15:47 Severe asthma biomarkers

21:23 IL-4, IL-13, TSLP: Promising pathways

25:49 Severe asthma diagnostic clues

28:34 Asthma biologic decision-making

35:31 How long-term is a biologic therapy?

37:44 The future of asthma-modifying therapy

41:09 Understanding asthmatic COVID-19 risk

44:57 Outro